Commercial Channels

Results of the Phase III CENTERSTONE study demonstrated that when Xofluza is taken by an individual with influenza, it lowers the risk of others in the household contracting it.

It’s essential for commercial success, but presents its share of obstacles.

A pooled analysis of the SWIFT-1 and SWIFT-2 trials found 54% reduction in exacerbation rates over 52 weeks in patients with severe asthma with type 2 inflammation treated with depemokimab.

This year’s conference—taking place in Washington, DC— will prioritize the tackling of business, economic, and healthcare policy obstacles when it comes to decision marking and net revenue optimization.

ROCTAVIAN will only be sold to the United States, Italian, and German markets, as the company eyes its profitability by 2025.

The parties will continue to create new candidate therapies for the treatment of a severe form of TUBB4A leukodystrophy.

Expansion of these offerings will occur at the company’s 60,000 square-foot Lincolnshire Center of Excellence

Ashfield Event Experiences and WRG merge in an effort to better serve the healthcare industry.

Biosimilars market experiences massive growth, but regulatory and adoption challenges remain.

The CDMO’s multi-million-dollar expansion project features commercial manufacturing suites and peptide manufacturing plants.

As part of the agreement, Novo will be paid both development and commercial milestone payments for NN-8828, is currently in Phase II of non-dermatological indications.

The partnership revolves around meeting various agency standards and industry requirements pertaining to the drug development and manufacturing lifecycle.

Properly supporting market access for a newly launched product with a single indication is challenging. Doing so for multiple indications, or supporting subsequent indications, can have a compounding effect on the degree of difficulty for getting everything right.

Per the deal, the company establishes Regeneron Cell Medicines, while also providing it with access to the collection’s full development and commercialization rights.

LillyDirect will facilitate access to medications by connecting patients with independent telehealth providers, bypassing the need to obtain a prescription from a physician and then going to a pharmacy to fill it.

Popular works in the category explore 340B guidelines, ‘smart pharma’ capabilities, and commercialization trends.

Session discusses ways to integrate digital pharmacies and hubs.

Panel uncovers ways to handle the increasing complexities and risks surrounding commercialization.

Conference keynote offers an industry outlook, including new commercialization challenges.

A study explores how supply and demand impact the value of medication.

Webinar Date/Time: Thu, Dec 14, 2023 11:00 AM EST

Financial commitment further strengthens IntegriChain’s platform as a source for pharma manufacturers' commercialization and market access goals.

Bill Roth provides insight as to how where chief commercial officers and access leaders can plan for a profitable product lifecycle.

How drugmakers can better harness real-world evidence to drive their clinical and commercial objectives, while also providing greater clarity for healthcare providers and improved access to therapy for the patients they serve.

The conference will focus on the full breadth of commercialization strategies and operations.

A look into ways to approach change management using three factors.

The company anticipates that the offering will help maximize life sciences brands’ commercial potential.

How the ‘fight-for-the-dollar’ is coming and likely will impact the bundled pricing of industry stakeholders.

Sy Pretorius, COO & president of outsourced solutions at Eversana, dives into his new role in the space, after being a veteran in the clinical development sector.

New PC column explores commercialization trends and how pharma can adjust to the new squeeze of market, regulatory, pricing, and gross-to-net pressures.